VivoSeq
Other

Adult

0

Pipeline Programs↗

162

Active Trials↗

255

Companies Involved↗

Adult is an early-stage landscape with 0 programs across 255 companies. The most active players are Pfizer, Johnson & Johnson, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

86/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

1,236

clinical trials

Completed949 · 77%
Recruiting84 · 7%
Terminated51 · 4%
Unknown status45 · 4%
Not yet recruiting41 · 3%
Active, not recruiting32 · 3%
Other34 · 3%

Clinical Trials

Trial Activity

1236 trials

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
Recruiting·Boryung Pharmaceutical Co., Ltd logoBoryung Pharmaceutical Co., Ltd·Phase 1·NCT07083388·52 enrolled
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Recruiting·GSK logoGSK·Phase 1·NCT05418868·214 enrolled
A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults
Recruiting·DDragonfly Therapeutics·Phase 1·NCT07232121·64 enrolled
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
Recruiting·Boryung Pharmaceutical Co., Ltd logoBoryung Pharmaceutical Co., Ltd·Phase 1·NCT07083401·40 enrolled
Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults
Recruiting·UUniversity of Saskatchewan·Phase 1·NCT06574100·20 enrolled
A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults
Recruiting·SScholar Rock, Inc.·Phase 1·NCT07444294·76 enrolled
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd. logoChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT07366866·48 enrolled
A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants
Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1·NCT06612970·46 enrolled
A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults
Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd. logoChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT07473570·32 enrolled
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Recruiting·Pfizer logoPfizer·Phase 1·NCT06994897·92 enrolled
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants
Recruiting·NNewsoara Biopharma Co., Ltd.·Phase 1·NCT07281703·60 enrolled
Novel Mucosal Correlates Of RSV Protection In Older Adults
Recruiting·IImperial College London·N/A·NCT06274619·20 enrolled
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Recruiting·Otsuka logoOtsuka·Phase 3·NCT06926829·180 enrolled
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Recruiting·Pfizer logoPfizer·Phase 1·NCT06564389·119 enrolled
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
Recruiting·YYuhan Corporation·Phase 1·NCT06517914·86 enrolled
Page 1 of 83

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)